On Nov 05, 2025, XNCR reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.70 USD, resulting in a 88.61% surprise. Revenue reached 21.00 million, compared to an expected 27.70 million, with a -24.18% difference. The market reacted with a -2.57% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.61 USD, with revenue projected to reach 32.32 million USD, implying an increase of 662.50% EPS, and increase of 53.91% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Xencor, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Xencor, Inc. reported EPS of -$0.08, beating estimates by 88.61%, and revenue of $21.00M, -24.18% below expectations.
How did the market react to Xencor, Inc.'s Q3 2025 earnings?
The stock price moved down -2.57%, changed from $14.37 before the earnings release to $14.00 the day after.
When is Xencor, Inc. expected to report next?
The next earning report is scheduled for Mar 04, 2026.
What are the forecasts for Xencor, Inc.'s next earnings report?
Based on 15
analysts, Xencor, Inc. is expected to report EPS of -$0.61 and revenue of $32.32M for Q4 2025.